Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moderna Inc MRNA

Healthcare Biotechnology
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular... see more

Recent & Breaking News (NDAQ:MRNA)

Moderna to Report First Quarter Financial Results on Wednesday, May 4, 2022

Accesswire April 13, 2022

Jorge Gomez Joins Moderna as Chief Financial Officer

Accesswire April 11, 2022

Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates

Accesswire April 11, 2022

IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies

Accesswire April 7, 2022

Moderna Launches New Charitable Foundation

Accesswire April 4, 2022

Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273

Accesswire March 29, 2022

Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day

Accesswire March 24, 2022

Moderna Finalizes Strategic Partnership with Australian Government

Accesswire March 23, 2022

Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint

Accesswire March 23, 2022

UMass Chan Medical School announces research collaboration with Moderna to examine impact of Cytomegalovirus (CMV) in young children

PR Newswire March 22, 2022

Moderna Announces New Development Programs Ahead of 3rd Annual Vaccines Day

Accesswire March 22, 2022

Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine

Accesswire March 21, 2022

Health Canada Approves Moderna COVID Vaccine for Kids 6-11

Stockhouse Editorial March 18, 2022

Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.

Accesswire March 17, 2022

Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)

Accesswire March 17, 2022

Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna's COVID-19 Booster Vaccine

Accesswire March 16, 2022

Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine

Accesswire March 14, 2022

Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate

Accesswire March 10, 2022

Moderna to Host Third Annual Virtual Vaccines Day on March 24, 2022

Accesswire March 10, 2022

Moderna Announces Its Global Public Health Strategy

Accesswire March 7, 2022